Understanding Medulloblastoma and the KMT2D Gene
Heterozygous KMT2D Loss and Medulloblastoma
['FUNDING_R01'] · UNIVERSITY OF TX MD ANDERSON CAN CTR · NIH-11142633
This work aims to uncover new ways that medulloblastoma, a common brain tumor in children, develops, focusing on changes in a gene called KMT2D.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF TX MD ANDERSON CAN CTR (nih funded) |
| Locations | 1 site (HOUSTON, UNITED STATES) |
| Trial ID | NIH-11142633 on ClinicalTrials.gov |
What this research studies
Medulloblastoma is a serious brain tumor in children, and current treatments often have severe side effects and don't always work. We need new ways to understand how this cancer starts and grows to develop better, more targeted treatments. This project explores how changes in gene expression, known as epigenetic changes, and specifically a gene called KMT2D, contribute to medulloblastoma. By understanding these fundamental processes, we hope to find new targets for future therapies.
Who could benefit from this research
Good fit: This foundational research is for anyone interested in the underlying causes of medulloblastoma, particularly those affected by this childhood brain tumor.
Not a fit: Patients seeking immediate new treatments will not directly benefit from this basic science project, as it focuses on understanding disease mechanisms rather than clinical trials.
Why it matters
Potential benefit: If successful, this work could lead to a deeper understanding of medulloblastoma, paving the way for new, more effective treatments with fewer side effects for children.
How similar studies have performed: While some pathways in medulloblastoma are well-known, this project explores a novel mechanistic understanding of epigenetic changes, addressing an unmet need in treatment development.
Where this research is happening
HOUSTON, UNITED STATES
- UNIVERSITY OF TX MD ANDERSON CAN CTR — HOUSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LEE, MIN GYU — UNIVERSITY OF TX MD ANDERSON CAN CTR
- Study coordinator: LEE, MIN GYU
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancer Suppressor Genes